Anders Tuv is investment director of the early-stage life science investment company Radforsk, which is focused on immunotherapies and precision medicines. He is an experienced investment and business development professional with broad experience from the life science industry covering management positions, strategy and business development, research collaborations, licensing deals, M&A and IPOs. He holds several chairman and non-executive director positions in Norwegian biotech companies. He holds an MBE degree.
Einar J. Greve works as a strategic advisor with Cipriano AS. He was previously a partner of Wikborg Rein & Co and a partner of Arctic Securities ASA. He has held and holds various positions as chairman and board member of both Norwegian and international listed and unlisted companies. He holds a master of law degree (cand.jur.) from the University of Oslo.
Jan Haudemann-Andersen is the sole owner of Datum AS and Datum Invest AS, and a major shareholder of Vaccibody. He has extensive investment experience from private and listed companies in Norway and abroad. He holds a business degree (siviløkonom) from the BI Norwegian Business School.
Trygve Lauvdal is an Investment Director with Rasmussengruppen which he joined in 2010. Prior to joining Rasmussengruppen, he worked as an equity analyst in DNB Markets and as product manager in ABB. Trygve is a PhD in Engineering Cybernetics from Norwegian University of Science and Technology (NTNU). Trygve has held several board positions in Norwegian companies.
Lars Lund-Roland is a business and management consultant and has a background in pharmaceutical marketing and business. Past employments include managerial and marketing positions with Merck & Co. Inc., MSD Norway and Bringwell AB. He serves as chairman of the board of the Norwegian Life Science Cluster, Palion Medical AS, SonoClear AS and Nisonic AS. He holds a BSc degree in nursing and a graduate diploma in business and administration (Bedriftsøkonomisk Kandidat) from the BI Norwegian Business School.
Bernd R. Seizinger serves as chairman or board member of a number of public and private biotech companies in the U.S., Canada and Europe, including Oxford BioTherapeutics, Aprea, CryptoMedix and Oncolytics. In addition, he serves on the advisory board of Pureos Ventures (BB Biotech/Bank Bellevue, Zurich) and is senior advisor to Hadean Ventures (Stockholm and Oslo). Prior managerial positions include Opsona, GPC Biotech, Genome Therapeutics Corporation and Bristol-Myers Squibb. He is a medical doctor and holds a Ph.D. in neurobiology.
Dr. Volck has served as the President R&D at AVROBIO Inc. (Nasdaq), a clinical stage gene therapy company. Prior to this, she served as head of Research and Development, Rare Diseases, for GlaxoSmithKline. Before that, Dr. Volck was the Chief Medical Officer and Senior Vice President of Development at Swedish Orphan Biovitrum AB. She has held various positions at Amgen Inc., including Executive Development Director, Bone, Neuroscience & Inflammation. She currently serves as Director of Ascendis Pharma A/S (Nasdaq) and Soleno Therapeutics Inc. (Nasdaq). Dr. Volck received her M.D. and Ph.D. degrees from Copenhagen University, Denmark.
Christian Åbyholm is a partner at Andenæsgruppen. His prior professional experience and past employments include M&A, business development and equity research with Norsk Hydro, Aker RGI, Morgan Stanley and Merrill Lynch. He is a CFA charterholder, has an MBA from IMD and a business degree (siviløkonom) from the Norwegian School of Economics and Business Administration. In addition, he completed the first two years of law school at the University of Oslo.